[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonspecific-interstitial-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonspecific-interstitial-pneumonia":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100347151","skeletal-muscle-function-in-interstitial-lung-disease-100347151",false,"NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body",true,"ALL","40 Years","80 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[28,29,30,31,32],"Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis","Scleroderma","Nonspecific Interstitial Pneumonia","RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":37},"2024-08-07",{"date":41,"type":22},"2026-12-31",{"name":43,"class":44},"University of British Columbia","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100439826","ild-sards-registry-and-biorepository-100439826","NCT05007340","ILD-SARDs Registry and Biorepository","Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository","ILD-SARDs","Inclusion Criteria:\n\n1. Must be aged 18 years or older\n2. Diagnosis of ILD as confirmed by a chest CT\n3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD\n4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.\n\nExclusion Criteria:\n\nN\u002FA","18 Years",{"count":56,"type":22},252,"5 Years","OBSERVATIONAL","A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs.\n\nThe purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.",[28,61,62,63,64,65,66,67,32],"Systemic Autoimmune Disease","Rheumatic Diseases","Rheumatic Arthritis","Systemic Sclerosis","Autoimmune Myositis","Systemic Lupus Erythematosus","Usual Interstitial Pneumonia",[28,61,62,63,64,65,66,67,32],"2021-09-01",{"date":71,"type":37},"2021-09-09",{"date":73,"type":37},"2021-08-24",{"date":75,"type":22},"2026-08",{"name":77,"class":44},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]